Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Goldman Sachs to hold a virtual conference » 04:55
06/10/21
06/10
04:55
06/10/21
04:55
ALNY

Alnylam

$157.41 /

+6.49 (+4.30%)

, FOLD

Amicus

$10.57 /

+0.19 (+1.83%)

, BTAI

BioXcel Therapeutics

$38.91 /

+0.97 (+2.56%)

, TXG

10x Genomics

$185.82 /

-1.29 (-0.69%)

, RPRX

Royalty Pharma

$45.99 /

-0.455 (-0.98%)

, TCDA

Tricida

$4.88 /

+0.16 (+3.39%)

, NEO

NeoGenomics

$42.62 /

+0.72 (+1.72%)

, VIR

Vir Biotechnology

$46.51 /

-0.03 (-0.06%)

, KRON

Kronos Bio

$26.78 /

-0.66 (-2.41%)

, BVS

Bioventus

$17.54 /

+0.42 (+2.45%)

, BHVN

Biohaven Pharmaceutical

$97.57 /

+2.34 (+2.46%)

, RXRX

Recursion Pharmaceuticals

$30.20 /

+0.46 (+1.55%)

, EXEL

Exelixis

$22.78 /

+0.575 (+2.59%)

, DSGN

Design Therapeutics

$27.48 /

-0.02 (-0.07%)

, ARNA

Arena Pharmaceuticals

$62.27 /

+1.3 (+2.13%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on June 8-10.

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
FOLD Amicus
$10.57 /

+0.19 (+1.83%)

05/27/21 Needham
Amicus initiated with a Hold at Needham
05/27/21 Needham
Amicus initiated with a Hold at Needham
05/20/21 UBS
Amicus initiated with a Buy at UBS
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 William Blair
10x Genomics initiated with an Outperform at William Blair
02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

06/03/21 SVB Leerink
MorphoSys upgraded to Outperform at SVB Leerink
11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
TCDA Tricida
$4.88 /

+0.16 (+3.39%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
BVS Bioventus
$17.54 /

+0.42 (+2.45%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

06/01/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $140 from $125 at Cantor Fitzgerald
05/28/21 Mizuho
Biohaven approval should lift 'important overhang,' says Mizuho
05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/12/21 SVB Leerink
Biohaven Pharmaceutical price target lowered to $105 from $115 at SVB Leerink
RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

05/11/21
Fly Intel: Top five analyst initiations
05/11/21 SVB Leerink
SVB Leerink bullish on Recursion Pharmaceuticals, initiates with an Outperform
05/11/21 BofA
BofA starts Recursion Pharmaceuticals at Buy with $31 price target
05/11/21 SVB Leerink
Recursion Pharmaceuticals initiated with an Outperform at SVB Leerink
EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

05/19/21 Piper Sandler
Reata news should be good for Design Therapeutics, says Piper Sandler
04/20/21 SVB Leerink
SVB Leerink bullish on Design Therapeutics, initiates with an Outperform
04/20/21 SVB Leerink
Design Therapeutics initiated with an Outperform at SVB Leerink
04/20/21 Piper Sandler
Design Therapeutics initiated with an Overweight at Piper Sandler
ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

05/18/21 Goldman Sachs
Arena Pharmaceuticals initiated with a Buy at Goldman Sachs
04/27/21 Citi
Arena Pharmaceuticals initiated with a Buy at Citi
04/26/21 Credit Suisse
Arena Pharmaceuticals assumed with an Outperform at Credit Suisse
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

  • 16
    Apr
  • 26
    Mar
  • 16
    Mar
  • 11
    Feb
  • 07
    Jan
  • 16
    Oct
  • 09
    Oct
  • 11
    Sep
  • 29
    Jul
  • 08
    Jul
  • 16
    Jun
FOLD Amicus
$10.57 /

+0.19 (+1.83%)

VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

Conference/Events
Goldman Sachs to hold a virtual conference » 11:22
06/09/21
06/09
11:22
06/09/21
11:22
ALNY

Alnylam

$155.41 /

+4.49 (+2.98%)

, FOLD

Amicus

$10.64 /

+0.26 (+2.50%)

, BTAI

BioXcel Therapeutics

$38.75 /

+0.81 (+2.13%)

, TXG

10x Genomics

$188.69 /

+1.58 (+0.84%)

, RPRX

Royalty Pharma

$46.36 /

-0.085 (-0.18%)

, TCDA

Tricida

$4.99 /

+0.27 (+5.72%)

, NEO

NeoGenomics

$42.86 /

+0.96 (+2.29%)

, VIR

Vir Biotechnology

$46.90 /

+0.36 (+0.77%)

, KRON

Kronos Bio

$27.57 /

+0.13 (+0.47%)

, BVS

Bioventus

$17.62 /

+0.5 (+2.92%)

, BHVN

Biohaven Pharmaceutical

$95.97 /

+0.74 (+0.78%)

, RXRX

Recursion Pharmaceuticals

$30.10 /

+0.36 (+1.21%)

, EXEL

Exelixis

$22.47 /

+0.265 (+1.19%)

, DSGN

Design Therapeutics

$27.96 /

+0.46 (+1.67%)

, ARNA

Arena Pharmaceuticals

$61.87 /

+0.9 (+1.48%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on June 8-10.

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
FOLD Amicus
$10.64 /

+0.26 (+2.50%)

05/27/21 Needham
Amicus initiated with a Hold at Needham
05/27/21 Needham
Amicus initiated with a Hold at Needham
05/20/21 UBS
Amicus initiated with a Buy at UBS
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 William Blair
10x Genomics initiated with an Outperform at William Blair
02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

06/03/21 SVB Leerink
MorphoSys upgraded to Outperform at SVB Leerink
11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
TCDA Tricida
$4.99 /

+0.27 (+5.72%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
BVS Bioventus
$17.62 /

+0.5 (+2.92%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

06/01/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $140 from $125 at Cantor Fitzgerald
05/28/21 Mizuho
Biohaven approval should lift 'important overhang,' says Mizuho
05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/12/21 SVB Leerink
Biohaven Pharmaceutical price target lowered to $105 from $115 at SVB Leerink
RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

05/11/21
Fly Intel: Top five analyst initiations
05/11/21 SVB Leerink
SVB Leerink bullish on Recursion Pharmaceuticals, initiates with an Outperform
05/11/21 BofA
BofA starts Recursion Pharmaceuticals at Buy with $31 price target
05/11/21 SVB Leerink
Recursion Pharmaceuticals initiated with an Outperform at SVB Leerink
EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

05/19/21 Piper Sandler
Reata news should be good for Design Therapeutics, says Piper Sandler
04/20/21 SVB Leerink
SVB Leerink bullish on Design Therapeutics, initiates with an Outperform
04/20/21 SVB Leerink
Design Therapeutics initiated with an Outperform at SVB Leerink
04/20/21 Piper Sandler
Design Therapeutics initiated with an Overweight at Piper Sandler
ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

05/18/21 Goldman Sachs
Arena Pharmaceuticals initiated with a Buy at Goldman Sachs
04/27/21 Citi
Arena Pharmaceuticals initiated with a Buy at Citi
04/26/21 Credit Suisse
Arena Pharmaceuticals assumed with an Outperform at Credit Suisse
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

  • 16
    Apr
  • 26
    Mar
  • 16
    Mar
  • 11
    Feb
  • 07
    Jan
  • 16
    Oct
  • 09
    Oct
  • 11
    Sep
  • 29
    Jul
  • 08
    Jul
  • 16
    Jun
FOLD Amicus
$10.64 /

+0.26 (+2.50%)

VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

Hot Stocks
Tela Bio appoints John Nosenzo to board of directors » 07:19
06/02/21
06/02
07:19
06/02/21
07:19
TELA

Tela Bio

$13.19 /

-0.83 (-5.92%)

, BVS

Bioventus

$17.82 /

+0.05 (+0.28%)

TELA Bio (TELA) announced…

TELA Bio (TELA) announced that it has appointed John Nosenzo, the CCO of Bioventus (BVS), to its board of directors effective June 2, 2021. Concurrent with the appointment of John Nosenzo, as previously announced, current board member Adele Olivia will be stepping down. Following these changes, TELA Bio's board will be composed of seven directors, six of whom are independent.

ShowHide Related Items >><<
TELA Tela Bio
$13.19 /

-0.83 (-5.92%)

BVS Bioventus
$17.82 /

+0.05 (+0.28%)

TELA Tela Bio
$13.19 /

-0.83 (-5.92%)

04/12/21 Piper Sandler
Reviews of Tela Bio's OviTex from two KOLs were positive, says Piper Sandler
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
03/25/21 Canaccord
Tela Bio pieces in place for accelerating growth, says Canaccord
01/14/21 Piper Sandler
Piper says Tela Bio momentum looks 'healthy' despite 'slight' Q4 miss
BVS Bioventus
$17.82 /

+0.05 (+0.28%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
TELA Tela Bio
$13.19 /

-0.83 (-5.92%)

BVS Bioventus
$17.82 /

+0.05 (+0.28%)

  • 11
    Feb
  • 26
    Jun
BVS Bioventus
$17.82 /

+0.05 (+0.28%)

Hot Stocks
Bioventus announces results from model evaluating PTP-001 » 09:03
05/25/21
05/25
09:03
05/25/21
09:03
BVS

Bioventus

$16.76 /

-0.1 (-0.59%)

Bioventus announced human…

Bioventus announced human placental tissue, prepared as a particulate composition, termed PTP-001, was shown to contain an array of beneficial growth factors, cytokines and anti-inflammatory molecules, which significantly reduced pain and cartilage degeneration in a rat osteoarthritis model. The in vivo activity of PTP-001 on joint pain and histopathology was evaluated in a rat model of OA that was induced surgically by destabilization of the medial meniscus. In the model, PTP-001 significantly reduced pain responses throughout six weeks post-dosing as compared to a saline treatment. The magnitude and duration of pain reduction following a single intra-articular treatment with PTP-001 was comparable to that observed for animals treated with a corticosteroid. For rats that received two doses of PTP-001, administered two weeks apart, significant reductions in cartilage degeneration scores were also observed. "We believe that PTP-001 represents a promising biologic candidate for osteoarthritis, with a multi-modal potential mechanism of action that may contribute to symptom management and disease modification," said Carl Flannery Senior Director, Scientific Affairs, Bioventus. "We will continue with further research and development of PTP-001, as we believe it represents a novel approach for the treatment of OA, and potentially other musculoskeletal conditions with unmet clinical need."

ShowHide Related Items >><<
BVS Bioventus
$16.76 /

-0.1 (-0.59%)

BVS Bioventus
$16.76 /

-0.1 (-0.59%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BVS Bioventus
$16.76 /

-0.1 (-0.59%)

  • 11
    Feb
BVS Bioventus
$16.76 /

-0.1 (-0.59%)

Over a month ago
Conference/Events
Canaccord Genuity to hold a virtual conference » 10:02
05/20/21
05/20
10:02
05/20/21
10:02
BVS

Bioventus

$16.12 /

+ (+0.00%)

, ANIK

Anika Therapeutics

$42.48 /

+0.45 (+1.07%)

, VCEL

Vericel

$52.10 /

+0.4 (+0.77%)

, MDXG

MiMedx

$9.60 /

+0.16 (+1.69%)

, CFMS

Conformis

/

+

, AXGN

AxoGen

$20.80 /

-0.05 (-0.24%)

, NUVA

NuVasive

$70.36 /

-0.02 (-0.03%)

, SPNE

SeaSpine

$20.22 /

-0.22 (-1.08%)

, ATEC

Alphatec

$15.01 /

+0.07 (+0.47%)

, THTX

Theratechnologies

$3.67 /

+ (+0.00%)

, MSON

Misonix

$19.44 /

+0.08 (+0.41%)

, DYNT

Dynatronics

$1.10 /

-0.02 (-1.79%)

Musculoskeletal Virtual…

Musculoskeletal Virtual Conference 2021 will be held on May 20.

ShowHide Related Items >><<
VCEL Vericel
$52.10 /

+0.4 (+0.77%)

THTX Theratechnologies
$3.67 /

+ (+0.00%)

SPNE SeaSpine
$20.22 /

-0.22 (-1.08%)

NUVA NuVasive
$70.36 /

-0.02 (-0.03%)

MSON Misonix
$19.44 /

+0.08 (+0.41%)

MDXG MiMedx
$9.60 /

+0.16 (+1.69%)

DYNT Dynatronics
$1.10 /

-0.02 (-1.79%)

CFMS Conformis
/

+

BVS Bioventus
$16.12 /

+ (+0.00%)

AXGN AxoGen
$20.80 /

-0.05 (-0.24%)

ATEC Alphatec
$15.01 /

+0.07 (+0.47%)

BVS Bioventus
$16.12 /

+ (+0.00%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
ANIK Anika Therapeutics
$42.48 /

+0.45 (+1.07%)

12/16/20 Barrington
Anika Therapeutics upgraded to Outperform with $43 target at Barrington
12/16/20 Barrington
Anika Therapeutics upgraded to Outperform from Market Perform at Barrington
VCEL Vericel
$52.10 /

+0.4 (+0.77%)

05/06/21 H.C. Wainwright
Vericel price target raised to $65 from $60 at H.C. Wainwright
02/25/21 SVB Leerink
Vericel price target raised to $60 from $50 at SVB Leerink
02/22/21 BTIG
Vericel price target raised to $56 from $45 at BTIG
02/16/21 Truist
Vericel price target raised to $60 from $40 at Truist
MDXG MiMedx
$9.60 /

+0.16 (+1.69%)

03/19/21 H.C. Wainwright
MiMedx initiated with a Buy at H.C. Wainwright
CFMS Conformis
/

+

03/04/21 Canaccord
Conformis undervalued despite momentum, says Canaccord
AXGN AxoGen
$20.80 /

-0.05 (-0.24%)

01/12/21 Cantor Fitzgerald
AxoGen price target raised to $23 from $16 at Cantor Fitzgerald
10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
NUVA NuVasive
$70.36 /

-0.02 (-0.03%)

05/06/21 Piper Sandler
NuVasive price target raised to $80 from $75 at Piper Sandler
04/27/21 Truist
NuVasive price target raised to $80 from $68 at Truist
04/05/21 Piper Sandler
FDA appears to approve NuVasive two-level indication, says Piper Sandler
03/26/21 Piper Sandler
NuVasive price target raised to $75 from $68 at Piper Sandler
SPNE SeaSpine
$20.22 /

-0.22 (-1.08%)

04/08/21 Wells Fargo
SeaSpine upgraded to Overweight from Equal Weight at Wells Fargo
04/08/21 Wells Fargo
SeaSpine upgraded to Overweight from Equal Weight at Wells Fargo
04/06/21 BTIG
SeaSpine price target raised to $28 from $25 at BTIG
03/24/21 Canaccord
Canaccord likes what 7D acquisition brings to SeaSpine Holdings
ATEC Alphatec
$15.01 /

+0.07 (+0.47%)

04/08/21 Piper Sandler
Alphatec CFO change 'surprising but manageable,' says Piper Sandler
03/05/21 H.C. Wainwright
Alphatec price target raised to $19 from $16 at H.C. Wainwright
03/05/21 Piper Sandler
Alphatec price target raised to $19 from $17 at Piper Sandler
01/29/21 Piper Sandler
Alphatec price target raised to $17 from $12 at Piper Sandler
THTX Theratechnologies
$3.67 /

+ (+0.00%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
MSON Misonix
$19.44 /

+0.08 (+0.41%)

07/13/20 Craig-Hallum
Misonix price target raised to $23 from $18 at Craig-Hallum
DYNT Dynatronics
$1.10 /

-0.02 (-1.79%)

VCEL Vericel
$52.10 /

+0.4 (+0.77%)

THTX Theratechnologies
$3.67 /

+ (+0.00%)

SPNE SeaSpine
$20.22 /

-0.22 (-1.08%)

NUVA NuVasive
$70.36 /

-0.02 (-0.03%)

MSON Misonix
$19.44 /

+0.08 (+0.41%)

MDXG MiMedx
$9.60 /

+0.16 (+1.69%)

CFMS Conformis
/

+

BVS Bioventus
$16.12 /

+ (+0.00%)

AXGN AxoGen
$20.80 /

-0.05 (-0.24%)

ATEC Alphatec
$15.01 /

+0.07 (+0.47%)

  • 16
    Apr
  • 12
    Feb
  • 11
    Feb
  • 14
    Oct
  • 24
    Sep
VCEL Vericel
$52.10 /

+0.4 (+0.77%)

SPNE SeaSpine
$20.22 /

-0.22 (-1.08%)

MSON Misonix
$19.44 /

+0.08 (+0.41%)

CFMS Conformis
/

+

BVS Bioventus
$16.12 /

+ (+0.00%)

ATEC Alphatec
$15.01 /

+0.07 (+0.47%)

Earnings
Bioventus reports Q1 non-GAAP EPS 15c, consensus 9c » 17:19
05/12/21
05/12
17:19
05/12/21
17:19
BVS

Bioventus

$15.37 /

-0.4 (-2.54%)

Reports Q1 revenue…

Reports Q1 revenue $81.8M, consensus $76.54M. The company said, "We were also pleased to announce an important strategic acquisition at the end of the first quarter and welcome the Bioness organization to our Bioventus team. Bioness is a recognized leader in neuromodulation through its innovative peripheral nerve stimulation therapy, and advanced rehabilitation medical devices. Our acquisition of Bioness significantly expands our total addressable market as their medical devices currently address a global market opportunity in excess of $8 billion. We view the Bioness acquisition as an attractive strategic addition in multiple ways including being accretive to our long-term growth profile, leveraging our significant customer presence across orthopedics, broadening our portfolio and increasing our global footprint."

ShowHide Related Items >><<
BVS Bioventus
$15.37 /

-0.4 (-2.54%)

BVS Bioventus
$15.37 /

-0.4 (-2.54%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BVS Bioventus
$15.37 /

-0.4 (-2.54%)

  • 11
    Feb
BVS Bioventus
$15.37 /

-0.4 (-2.54%)

Earnings
Bioventus sees FY21 revenue $394M-$406M, consensus $381.54M » 16:50
05/12/21
05/12
16:50
05/12/21
16:50
BVS

Bioventus

$15.37 /

-0.4 (-2.54%)

Sees FY21 adjusted EBITDA…

Sees FY21 adjusted EBITDA $73.9M-$80.9M. The company said, "We have updated our revenue guidance for 2021, driven by our results in the first quarter. Our updated guidance reflects total Company revenue growth in the range of 23% to 26% year-over-year, fueled primarily by anticipated strong organic growth* in the range of 13% to 16% year-over-year and contributions from our acquisition of Bioness for the remaining nine months of 2021. We have significantly enhanced our balance sheet and financial condition with the net proceeds raised in our IPO in February and believe we are well positioned to execute our strategy to accelerate our multi-year growth profile with continued progress in our clinical, product development and new product pipeline and our pursuit of in-organic business development opportunities."

ShowHide Related Items >><<
BVS Bioventus
$15.37 /

-0.4 (-2.54%)

BVS Bioventus
$15.37 /

-0.4 (-2.54%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BVS Bioventus
$15.37 /

-0.4 (-2.54%)

  • 11
    Feb
BVS Bioventus
$15.37 /

-0.4 (-2.54%)

Hot Stocks
Bioventus Inc (Class A Stock) trading resumes  14:32
05/10/21
05/10
14:32
05/10/21
14:32
BVS

Bioventus

$14.75 /

+0.08 (+0.55%)

 
ShowHide Related Items >><<
BVS Bioventus
$14.75 /

+0.08 (+0.55%)

BVS Bioventus
$14.75 /

+0.08 (+0.55%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BVS Bioventus
$14.75 /

+0.08 (+0.55%)

  • 11
    Feb
BVS Bioventus
$14.75 /

+0.08 (+0.55%)

Hot Stocks
Bioventus Inc (Class A Stock) trading halted, volatility trading pause  14:27
05/10/21
05/10
14:27
05/10/21
14:27
BVS

Bioventus

$14.75 /

+0.08 (+0.55%)

 
ShowHide Related Items >><<
BVS Bioventus
$14.75 /

+0.08 (+0.55%)

BVS Bioventus
$14.75 /

+0.08 (+0.55%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BVS Bioventus
$14.75 /

+0.08 (+0.55%)

  • 11
    Feb
BVS Bioventus
$14.75 /

+0.08 (+0.55%)

Hot Stocks
Bioventus announces first commercial shipment of BITS balance system » 08:36
04/27/21
04/27
08:36
04/27/21
08:36
BVS

Bioventus

$14.21 /

+0.17 (+1.21%)

Bioventus announced the…

Bioventus announced the first commercial shipments of the Bioness Integrated Therapy System, or BITS, for Balance. BITS Balance "accelerates the value of the BITS platform by adding over 40 new programs and assessments, leveraging proprietary motion sensing technology on any easy to use, adjustable balance platform. From independent physical therapy practices, to regional medical centers, and national providers, the technology will aid clinicians in challenging, assessing, and tracking patients' balance, stability, and strength, ultimately maximizing therapy outcomes," the company said.

ShowHide Related Items >><<
BVS Bioventus
$14.21 /

+0.17 (+1.21%)

BVS Bioventus
$14.21 /

+0.17 (+1.21%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BVS Bioventus
$14.21 /

+0.17 (+1.21%)

  • 11
    Feb
BVS Bioventus
$14.21 /

+0.17 (+1.21%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.